Melbourne, Australia: Neuren Pharmaceuticals (ASX: NEU) notes an article published in the Australian newspaper, which stated “Neuren Pharmaceuticals is understood to have brought in a defence adviser after fielding buyer interest from US-based industry giants”. Neuren appointed a corporate and strategic adviser several months ago. The appointment was a normal step in Neuren’s ongoing growth and development and not in response to any approaches from third parties. Media speculation to the contrary is unfounded.
Ann: Comment on media speculation, page-3
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$15.63 |
Change
-1.080(6.46%) |
Mkt cap ! $1.997B | |||
| Open | High | Low | Value | Volume |
| $16.61 | $16.65 | $15.54 | $8.354M | 529.4K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 830 | $15.60 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $15.74 | 1484 | 2 |
View Market Depth
| Last trade - 16.10pm 18/11/2024 (20 minute delay) ? |
| NEU (ASX) Chart |